<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21795">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02032212</url>
  </required_header>
  <id_info>
    <org_study_id>ITG EVP G1 S1</org_study_id>
    <nct_id>NCT02032212</nct_id>
  </id_info>
  <brief_title>A Bioavailability Study of Nicotine Delivered by an Electronic Vapour Product</brief_title>
  <official_title>A Randomised, Crossover, Relative Bioavailability Study of Nicotine Delivered by an Electronic Vapour Product, a Nicotine Inhalator and a Conventional Cigarette</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial Tobacco Group PLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial Tobacco Group PLC</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Electronic Vapour Products (EVPs) are a relatively new class of consumer products that are
      otherwise known as electronic cigarettes. These may look like conventional cigarettes but do
      not contain tobacco.

      The 'vapour' produced by such devices typically consists of humectants (propylene glycol or
      glycerol), nicotine, water, and flavours.

      This trial is to evaluate the pharmacokinetic profile of an EVP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The principal part of this study evaluates the nicotine pharmacokinetic profile of
      conventional cigarettes, a nicotine inhalator, an unflavoured EVP and a flavoured EVP.

      A second part investigates the nicotine delivery of an EVP with four different nicotine
      doses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Nicotine plasma concentration</measure>
    <time_frame>Up to 5 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve for plasma nicotine</measure>
    <time_frame>Up to 5 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Up to 5 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Craving and withdrawal symptoms</measure>
    <time_frame>Up to 5 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>EVP unflavoured</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unflavoured e-vapour product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVP flavoured</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flavoured e-vapour product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine inhalator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotine inhalator 15mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Cigarette</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional cigarette</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EVP unflavoured</intervention_name>
    <arm_group_label>EVP unflavoured</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EVP flavoured</intervention_name>
    <arm_group_label>EVP flavoured</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nicotine inhalator 15mg</intervention_name>
    <arm_group_label>Nicotine inhalator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional cigarette</intervention_name>
    <arm_group_label>Conventional Cigarette</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI of 18-35kg/m2

          -  Subjects must be established smokers

          -  Subjects must have smoked five to 30 cigarettes per day for at least one year

        Exclusion Criteria:

          -  Subjects who have used nicotine replacement therapy within 14 days of the screening

          -  Subjects who have donated blood within 12 months preceding study

          -  Subjects with relevant illness history

          -  Subjects positive for hepatitis or HIV

          -  Subjects with history of drug or alcohol abuse

          -  Subjects with lung function test or vital signs considered unsuitable

          -  Subjects who are trying to stop smoking
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Girish Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simbec Research</name>
      <address>
        <city>Merthyr Tydfil</city>
        <state>Wales</state>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>January 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Nicotine polacrilex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
